Outcomes of cochlear implantation in patients with neurofibromatosis type 2.
In neurofibromatosis type 2 (NF2) bilateral vestibular schwannomas (VS) or their treatment usually results in bilateral hearing loss. Cochlear implantation (CI) was traditionally not used in these patients due to concern that retrocochlear disease would render the implant ineffective. This paper describes the auditory outcomes of CI in 13 patients with NF2 and includes patients with untreated VS and patients undergoing VS removal with cochlear nerve preservation. The non-user rate was 7.7%. Of the active users, median CUNY score was 98%, median BKB score in quiet was 90% and median BKB score in noise was 68%. CI is a viable option in selected patients with NF2.
a Department of Otolaryngology , Salford Royal NHS Foundation Trust , Manchester M6 8HD , UK.
Hannah J D
HJ
North
b The Richard Ramsden Centre for Auditory Implants, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester M13 9WL , UK.
Deborah
D
Mawman
b The Richard Ramsden Centre for Auditory Implants, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester M13 9WL , UK.
Martin
M
O'Driscoll
a Department of Otolaryngology , Salford Royal NHS Foundation Trust , Manchester M6 8HD , UK.|b The Richard Ramsden Centre for Auditory Implants, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester M13 9WL , UK.
Simon R
SR
Freeman
c Department of Neurosurgery , Salford Royal NHS Foundation Trust , Manchester M6 8HD , UK.
Scott A
SA
Rutherford
c Department of Neurosurgery , Salford Royal NHS Foundation Trust , Manchester M6 8HD , UK.
Andrew T
AT
King
c Department of Neurosurgery , Salford Royal NHS Foundation Trust , Manchester M6 8HD , UK.
Charlotte
C
Hammerbeck-Ward
d Manchester Centre for Genomic Medicine, University of Manchester, Manchester Academic Health Science Centre , Manchester M13 9WL , UK.|e Institute of Cancer Sciences, University of Manchester , UK.
D Gareth
DG
Evans
a Department of Otolaryngology , Salford Royal NHS Foundation Trust , Manchester M6 8HD , UK.|b The Richard Ramsden Centre for Auditory Implants, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester M13 9WL , UK.|e Institute of Cancer Sciences, University of Manchester , UK.
Simon K W
SK
Lloyd
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001301:Audiometry, Pure-Tone; D019929:Cochlear Implantation / Q000379:methods*; D003054:Cochlear Implants; D003056:Cochlear Nerve / Q000601:surgery; D005260:Female; D006309:Hearing / Q000502:physiology; D006312:Hearing Loss, Bilateral / Q000209:etiology / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016518:Neurofibromatosis 2 / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D009464:Neuroma, Acoustic / Q000209:etiology / Q000503:physiopathology / Q000601:surgery*; D012189:Retrospective Studies; D013067:Speech Perception / Q000502:physiology; D016896:Treatment Outcome; D055815:Young Adult
Auditory brainstem response; Cochlear implantation; Neurofibromatosis type 2; Vestibular schwannoma base of skull